Yondelis trabectedin regulatory update

Brazil, India and Argentina approved Yondelis trabectedin in combination with Caelyx peglyated liposomal doxorubicin to treat platinum-sensitive ovarian cancer. The cytotoxic alkaloid that binds the minor groove of DNA is now approved for the indication in 63 countries, including 30 outside the European Economic Area (EEA). PharmaMar, a subsidiary of Zeltia S.A. (Madrid:ZEL, Madrid, Spain), markets Yondelis in the EU, while Otsuka's Taiho Pharmaceuticals Co. Ltd. subsidiary holds exclusive rights in Japan. Johnson & Johnson has rights elsewhere. ...